기본 정보
- CAS
58957-92-9- 표준 SMILES
CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O- InChIKey
XDXDZDZNSLXDNA-TZNDIEGXSA-N- 분자식
- C26H27NO9
- 평균 분자량
- 497.5 g/mol
- 단동위원소 질량
- 497.16858144
개요
Idarubicin is a deoxy hexoside, an anthracycline antibiotic and a monosaccharide derivative. It derives from a hydride of a tetracene.
이름 및 식별자
- 우선 이름
- Idarubicin
- IUPAC
- (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
- 영어명
- Idarubicin
- 분자식
- C26H27NO9
- 분자량
- 497.49
이름 및 동의어
IDARUBICIN58957-92-94-Demethoxydaunorubicin4-DemethoxydaunomycinIdarubicinaIdarubicineIdarubicinumZavedosZRP63D75JWNSC 256439DTXSID7023142CHEBI:42068
이름 더 보기
DMDR4-DMDCS-704IMI-30IDAMYCINnsc-256439IDARUBICIN HCLIMI-30：NSC-256439Idarubicin USP/EP/BP
(7S,9S)-9-acetyl-7-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,9,11-trihydroxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione5,12-Naphthacenedione, 9-acetyl-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7S-cis)-(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside4-Desmethoxydaunorubicin4 Demethoxydaunorubicin(7S,9S)-9-acetyl-7-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl)oxy)-6,9,11-trihydroxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione4 DesmethoxydaunorubicinRefChem:56926
데이터베이스 식별자
- CAS
58957-92-9- PubChem CID
- 42890
- DTXSID
물성
구조 계산 물성
- XLogP
- 1.9
- 극성 표면적
- 177 Ų
- 수소 결합 공여자 수
- 5
- 수소 결합 수용자 수
- 10
- 회전 가능 결합 수
- 3
- 무거운 원자 수
- 36
- 형식 전하
- 0
- 복잡도
- 912
실험 및 물리화학적 성질
Drugs
Pharmaceuticals -> Antibiotics
Pharmaceuticals -> Listed in ZINC15
LogP0.2
Solubility7.72e-01 g/L
Human DrugsBreast Feeding; Lactation; Milk, Human; Antineoplastic Agents; Anthracyclines; Antibiotics, Antineoplastic; Topoisomerase II Inhibitors
Physical DescriptionSolid
물리화학적 성질
- 끓는 점
- 589.46 °C · 589.46°C (rough estimate)
- 밀도
- 1.3477 · 1.3477 (rough estimate)
- 굴절률
- 1.6 · 1.6000 (estimate)
- 저장 조건
- 2 · Keep in dark place,Sealed in dry,2-8°C
- 물리적 상태
- 고체
- 산도 계수 (pKa)
- 4.73 · pKa 4.73± 0.21 (Uncertain)
안전 및 규제
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
독성 정보
Drug Induced Liver Injury
Drug-Induced Liver Injury Severity and Toxicity (DILIst)
idarubicin
DILI Negative
Intravenous
DOI:10.1016/j.drudis.2019.09.022
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
안전 데이터
- wgk
- 3
- rtecs
- HB7877000
- ridadr
- UN 2811 6.1/PG 2
- risk_code
- 60-61-28-40
- hazard_code
- T+
- safety_code
- 53-45
화학 및 산업
약리 정보
ATC Code
L01DB06
L - Antineoplastic and immunomodulating agents
QL - Antineoplastic and immunomodulating agents
Protein Binding97%
Pharmacodynamics
Idarubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Idarubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Idarubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific.
Mechanism of Action
Idarubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Idarubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.
Biological Half-Life22 hours
FDA Pharmacological Classification
ZRP63D75JW
IDARUBICIN
Established Pharmacologic Class [EPC] - Anthracycline Topoisomerase Inhibitor
Chemical Structure [CS] - Anthracyclines
Mechanisms of Action [MoA] - Topoisomerase Inhibitors
Idarubicin is an Anthracycline Topoisomerase Inhibitor. The mechanism of action of idarubicin is as a Topoisomerase Inhibitor.
관련 반응
0건
현재 필터 조건에 해당하는 반응 기록이 없습니다.
화합물 노트
불러오는 중…